Clindoxyl (clindamycin and benzoylperoxide)
Clindoxyl gel is a combined drug for local treatment of light to moderate acne vulgaris. The gel consists of clindamycin and benzoylperoxide, and has bacteriostatic and bactericidal/keratolytic effects respectively.
The efficiency on inflammatory lesions in the face is moderately better than both placebo and monotherapy with adapalene (Redap), clindamycin (Dalacin) or benzoylperoxide (Basiron). Measured on comedones the efficiency is better compared to placebo or clindamycin. Adverse effects are local and occur to the same extent as with additional drugs.
The price of four weeks treatment is 195 Danish kroner, which is two to four times the price of the cheapest drug. The product is automatically reimbursement.
After opening the durability is two month.
According to IRF, Clindoxyl is a relevant supplement to the existing drugs for the treatment of inflammatory lesions.
Clindoxyl was marketed 8 May 2006.
Institute for Rational Pharmacotherapy, 29 May 2006